DRG 221 Overview

DRG 221 covers inpatient hospitalizations for cardiac valve and other major cardiothoracic procedures performed without cardiac catheterization and without Major Complication or Comorbidity. This Diagnosis-Related Group captures procedures such as isolated valve replacements or repairs and other major open thoracic operations when no higher-severity comorbid conditions are present. It matters for Medicare payment because the grouped classification determines base payment weights and influences resource intensity and reimbursement for hospitals under the inpatient prospective payment system. Accurate coding and documentation of procedures and comorbidities affect whether a case is assigned to this Diagnosis-Related Group and the resulting payment.

• Acute procedural optimization studies: randomized or prospective studies evaluating intraoperative strategies, surgical techniques, or perioperative management protocols for patients undergoing open cardiac valve replacement or major cardiothoracic procedures without concomitant cardiac catheterization. These trials enroll predominantly adult patients with severe valvular disease or complex thoracic pathology scheduled for index operative repair or replacement, and they measure intraoperative metrics (ischemic time, blood loss), early morbidity (bleeding, infection, arrhythmia), and 30-day mortality to define best practices. Results are directly relevant to surgeons, anesthesiologists, and hospital administrators because optimized intraoperative care can reduce complications, shorten ICU and inpatient length of stay, and therefore affect DRG resource use and reimbursement risk.
• Comparative effectiveness and device/technique studies: noninferiority or pragmatic trials comparing alternative valve prostheses (e.g., bioprosthetic vs mechanical where applicable), sutureless valves, or different surgical approaches (minimally invasive thoracotomy vs full sternotomy) in patients eligible for major cardiothoracic procedures without catheterization. These studies target subgroups such as older adults with multiple comorbidities, reoperative patients, or those with specific anatomic considerations, and they evaluate outcomes including valve function, reoperation rates, functional status, and mid-term survival. Payers and health systems use this evidence to inform coverage decisions, implant selection, and care pathways that balance device cost, durability, and downstream utilization within the DRG population.
• Post-discharge outcomes and care-transition research: cohort studies or randomized interventions testing enhanced recovery after surgery (ERAS) bundles, structured cardiac rehabilitation referral, remote monitoring, or readmission-prevention programs for survivors of major valve or cardiothoracic surgery. These trials focus on the early post-discharge period and enroll patients at hospital discharge, measuring readmissions, outpatient resource use, patient-reported outcomes, and cost-effectiveness over 30–90 days and up to 1 year. This research is important to providers and payers because reducing readmissions and improving functional recovery can lower total episode-of-care costs under the DRG payment model and improve quality metrics tied to reimbursement and value-based programs.